Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose atropine for near-focusing eye changes in progressive myopia
ACTRN12621000563864Phase 3Completed
- Sponsor
- Queensland University of Technology
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atropine in myopia, sponsored by Queensland University of Technology. Primary endpoints: Accommodation-induced variation in ocular biometry, Accommodation-induced variation in higher-order aberrations and 1 more. Started Jul 2021; status: completed.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on ACTRN12621000563864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000563864.